Evidence-based management guidelines for noncystic fibrosis bronchiectasis in children and adolescents
- Author:
Eun LEE
1
;
Kyunghoon KIM
;
You Hoon JEON
;
In Suk SOL
;
Jong Deok KIM
;
Taek Ki MIN
;
Yoon Ha HWANG
;
Hyun-Ju CHO
;
Dong In SUH
;
Hwan Soo KIM
;
Yoon Hee KIM
;
Sung-Il WOO
;
Yong Ju LEE
;
Sungsu JUNG
;
Hyeon-Jong YANG
;
Gwang Cheon JANG
Author Information
- Publication Type:Review Article
- From: Clinical and Experimental Pediatrics 2024;67(9):418-426
- CountryRepublic of Korea
- Language:English
- Abstract: Noncystic fibrosis bronchiectasis is a chronic respiratory disease that carries high socioeconomic and medical burdens and is caused by diverse respiratory illnesses. To improve clinical outcomes, early recognition, active treatment of exacerbations, and prevention of further exacerbations are essential. However, evidence for the treatment and prevention of acute exacerbation of noncystic fibrosis bronchiectasis, especially in children, is lacking. Therefore, the evidence- and consensus-based guidelines for medical and nonmedical treatment strategies for noncystic fibrosis bronchiectasis in children and adolescents were developed by the Korean Academy of Pediatric Allergy and Respiratory Disease using the methods recommended by the Grading of Recommendations Assessment, Development, and Evaluation working group with evidence published through July 2, 2020. This guideline encompasses evidence-based treatment recommendations as well as expert opinions, addressing crucial aspects of the treatment and management of non-cystic fibrosis bronchiectasis in children. This includes considerations for antibiotics and airway clearance strategies, particularly in areas where evidence may be limited. Large, well-designed, and controlled studies are required to accumulate further evidence of management strategies for noncystic fibrosis bronchiectasis in children and adolescents.
